Fmr LLC reduced its position in shares of Humana Inc (NYSE:HUM) by 19.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,937,033 shares of the insurance provider’s stock after selling 2,395,707 shares during the period. Fmr LLC owned about 0.07% of Humana worth $2,643,251,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Vanguard Group Inc boosted its position in shares of Humana by 1.4% during the third quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock worth $3,420,482,000 after buying an additional 140,864 shares during the period. BB&T Securities LLC boosted its holdings in Humana by 7.8% in the fourth quarter. BB&T Securities LLC now owns 4,572 shares of the insurance provider’s stock valued at $1,309,000 after purchasing an additional 331 shares during the period. Pinnacle Associates Ltd. boosted its holdings in Humana by 25.2% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,392 shares of the insurance provider’s stock valued at $399,000 after purchasing an additional 280 shares during the period. ClariVest Asset Management LLC boosted its holdings in Humana by 9.5% in the fourth quarter. ClariVest Asset Management LLC now owns 635 shares of the insurance provider’s stock valued at $182,000 after purchasing an additional 55 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in Humana by 5.0% in the fourth quarter. Victory Capital Management Inc. now owns 19,722 shares of the insurance provider’s stock valued at $5,650,000 after purchasing an additional 943 shares during the period. Institutional investors and hedge funds own 92.61% of the company’s stock.
Humana stock traded up $0.55 during midday trading on Monday, reaching $252.38. The company’s stock had a trading volume of 3,718 shares, compared to its average volume of 1,437,834. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The stock has a market cap of $34.01 billion, a PE ratio of 17.38, a P/E/G ratio of 1.04 and a beta of 0.85.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.30 by $0.18. Humana had a return on equity of 20.77% and a net margin of 2.99%. The company had revenue of $16.11 billion for the quarter, compared to analysts’ expectations of $15.67 billion. During the same period last year, the firm earned $3.36 earnings per share. Humana’s quarterly revenue was up 12.8% on a year-over-year basis. On average, research analysts expect that Humana Inc will post 17.48 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is currently 15.12%.
A number of research firms recently issued reports on HUM. UBS Group began coverage on Humana in a report on Tuesday, April 23rd. They issued a “neutral” rating and a $266.00 target price for the company. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. ValuEngine cut Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Citigroup cut their price target on Humana from $362.00 to $302.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Finally, SunTrust Banks cut their price target on Humana to $300.00 in a research note on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $337.26.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Dow Jones Industrial Average (DJIA)
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.